¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative specific activity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • specific absorption rate
    ºñÈí¼öÀ²
  • specific action
    ƯÀÌÀÛ¿ë
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific antigen
    ƯÀÌÇ׿ø
  • specific capsular reaction
    ƯÀÌÇǸ·¹ÝÀÀ
  • specific charge
    ºñÀüÇÏ, °ßÁÜÀüÇÏ
  • specific compliance
    ºñ¼øÀÀµµ
  • specific conductivity
    ºñÀüµµÀ²
  • specific death rate
    ƯÀÌ»ç¸Á·ü
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • specific fertility rate
    ƯÀÌ»ý½Ä·ü, ºñ»ý½Ä·ü
  • specific granule
    ƯÀ̰ú¸³
  • specific gravity
    ºñÁß
  • specific gravity test
    ºñÁß°Ë»ç
  • specific growth rate
    ƯÀÌÁõ½Ä·ü, ƯÀ̼ºÀå·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • specific action
    ƯÀÌÀÛ¿ë
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific antigen
    ƯÀÌÇ׿ø
  • specific pathogen free animal
    ƯÁ¤¹«º´¿øÃ¼µ¿¹°
  • type specific antigen
    ÇüƯÀÌÇ׿ø
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • cause-specific rate
    ¿øÀκ°Æ¯¼öÀ²
  • specific charge
    °ßÁÜÀüÇÏ, ºñÀüÇÏ
  • specific compliance
    ƯÀÌź¼º, ƯÀÌÀ¯¼øµµ, ƯÀÌÀÀ¶ô
  • specific conductivity
    ºñÀüµµÀ²
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • donor-specific phage
    Á¦°øÃ¼Æ¯ÀÌÆÄÁö, ÁÖ°ÔÆ¯ÀÌÆÄÁö
  • specific disease
    ƯÀÌÁúȯ
  • specific reading disability
    ƯÁ¤ÀбâÀå¾Ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • relative field
    ºñ±³¿µ¿ª(ÝïÎòçÐæ´).
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ(ËÓË´Ë×̬).
  • relative growth
    »ó´ëÀû »ýÀå(ßÓÓßîÜßæíþ)
  • relative hearing
    »ó´ë(Àû) û°¨
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£).
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£)
  • relative humidity
    »ó´ë½Àµµ
  • relative immunity
    »ó´ë¸é¿ª(¡­Øóæ¹).
  • relative incompetence
    »ó´ë¼º ºÎÀü(¡­àõÝÕîï).
  • relative incompetence
    »ó´ë¼º ºÎÀü(ßÓÓßàõÝÕîï)
  • relative leukocytosis
    ºñ±³¹éÇ÷±¸Áõ°¡Áõ(ÝïÎòÛÜúìϹñòÊ¥ñø).
  • relative leukocytosis
    ºñ±³¹éÇ÷±¸Áõ°¡Áõ(ÝïÎòÛÜúìϹñòÊ¥ñø)
  • relative measurement
    ºñ±³ÃøÁ¤(ËÓË´Ì¬Ëø).
  • relative metabolic rate
    »ó´ëÀû ´ë»çÀ².
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • activity therapy
    Ȱµ¿ ¿ä¹ý
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • activity, antibacterial
    Ç×±ÕÀÛ¿ë
  • amylase activity
    ¾Æ¹Ð¶óÁ¦-Ȱ¼ºµµ
  • antibacterial activity
    Ç×±ÕÀÛ¿ë(ù÷жíÂéÄ), Ç×±ÕȰ¼º(ù÷жüÀàõ).
  • bacteri(o)cidal activity
    »ì±Õ·Â.
  • binding activity
    °áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • binding activity
    ¸é¿ª°áÇÕȰ¼º(Ì¿ùêüÀàõ).
  • caries activity
    ¿ì½ÄȰµ¿¼º(ó»ãÚüÀÔÑàõ), ¿ì½ÄȰµ¿µµ(¡­öô).
  • displacement activity
    ÀüġȰµ¿
  • effect concentration(=activity)
    À¯È¿³óµµ(êóüùÒØÓø)
  • elastolytic activity
    ¿¤¶ó½ºÆ¾¿ëÇØÈ°¼º(µµ), ¿¤¶ó½ºÅ¸¾ÆÁ¦È°¼º(µµ).
  • enzyme activity
    È¿¼ÒȰ¼º
  • enzyme activity
    È¿¼ÒȰ¼ºµµ
  • epidemiologic activity
    ¿ªÇÐÀû Ȱµ¿(ËçÌ°Ëø Ì·ËÄ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • tissue-specific enzyme
    Á¶Á÷ ƯÀÌ È¿¼Ò (ðÚòÄ÷åì¶ý£áÈ)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
sp act specific activity
SSA salicylsalicylic acid; sicca syndrome A; skin-sensitizing antibody; skin sympathetic activity; Sjogr...
T4SA thyroxine-specific activity
CIA chemiluminescent immunoassay; chymotrypsin inhibitor activity; colony-inhibiting activity; congenita...
ECA electrical control activity; electrocardioanalyzer; endothelial cytotoxic activity; enterobacterial ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
RR relative rish
RSDs Relative Standard Deviations
RVU Relative Value Units
RAL Relative adduct labeling
RAPD Relative afferent pupillary defect
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • persistent activity
    Áö¼ÓÀûÀΠȰ¼º
  • phagocytic activity
    ½Ä¼¼Æ÷´É
  • play activity
    ³îÀÌ
  • postural electromyographic activity
    ÀÚ¼¼¼º ±ÙÀüµµ Ȱ¼º
  • reflex activity
    ¹Ý»ç Ȱµ¿
  • seizure activity
    ¹ßÀÛ¼º Ȱµ¿
  • serum diastase activity
    Ç÷û µð¾Æ½ºÅ¸Á¦Ä¡
    Ç÷û¿¡ ÇÔÀ¯µÈ ¾Æ¹Ð¶ó¾ÆÁ¦ÀÇ ¾çÀ» ³ªÅ¸³»´Âµ¥ »ç¿ëÇÑ´Ù.
  • social welfare activity
    »çȸ º¹Áö»ç¾÷
  • spontaneous activity
    ÀÚ¹ßÀû Ȱµ¿
  • sympathetic efferent activity
    ¿ø½É¼º ±³°¨½Å°æ Ȱµ¿, ¿ø½É¼º ±³°¨½Å°æ Ȱ¼º
  • sympathetic nervous system activity
    ±³°¨½Å°æ°è Ȱ¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
prenylated peptide-specific endoprotease <enzyme> Cleaves c-terminal tripeptide from prenylated protein having c-terminal sequence caax; race is rac and a-factor converting enzyme with same activity
Registry number: EC 3.4.14.-
Synonym: prenylated protein endoprotease, race enzyme, isoprenylated protein endopeptidase, isoprenylated protein endoprotease
(26 Jun 1999)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
proline-specific dipeptidylcarboxypeptidase <enzyme> From streptomyces species; removes diproline form c-terminus of proline-containing peptides such as boc-pro-pro-pro-pro or leu-pro-pro-pro-pro-pro
Registry number: EC 3.4.15.-
Synonym: pro-dpp-carboxypeptidase
(26 Jun 1999)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
pyrimidine-guanine sequence-specific ribonuclease <enzyme> From yolk granules of adult rana catesbeiana oocytes
Registry number: EC 3.1.27.-
Synonym: rc-rnase, rana catesbeiana rnase
(26 Jun 1999)
site-specific mutagenesis <cell culture, molecular biology> An in vitro technique in which an alteration is made at a specific site in a DNA molecule, which is then reintroduced into a cell. Various techniques are used, for the cell biologist, a very powerful approach to determining which parts of a protein or nucleotide sequence are critical to function.
(18 Nov 1997)
site specific mutation An alteration of the structure of a gene at a specific sequence, usually referring to experimentally produced changes in gene sequence.
(05 Mar 2000)
site-specific recombination <molecular biology> A type of recombination that occurs between two specific short DNA sequences present in the same or in different molecules. An example is the integration and excision of _ prophage.
(18 Nov 1997)
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
species-specific Applying only to a particular species, said of effects that vary depending on the species in question.
(09 Oct 1997)
species-specific antigen Antigenic components in the tissues and fluids of members of a species of animal, by means of which various species may be immunologically distinguished; e.g., serum albumin of horses is immunologically different from that of man, dogs, sheep, and so on.
(05 Mar 2000)
specific 1. Pertaining to a species.
2. Produces by a single kind of microorganism.
3. A remedy specially indicated for any particular disease.
4. <immunology> Pertaining to the special affinity of antigen for the corresponding antibody.
Origin: L. Specificus
(18 Nov 1997)
specific absorbance Absorbance per unit of concentration.
See: specific absorption coefficient.
(05 Mar 2000)
specific absorption coefficient Absorbance (of light) per unit path length (usually the centimeter) and per unit of mass concentration.
Compare: molar absorption coefficient.
Synonym: absorbancy index, absorptivity, extinction coefficient, specific extinction.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á